Universität zu Köln

Caprioglio, Camilla, Garibotto, Valentina, Jessen, Frank, Froelich, Lutz, Allali, Gilles, Assal, Frederic, Frisoni, Giovanni B. ORCID: 0000-0002-6419-1753 and Altomare, Daniele ORCID: 0000-0003-1905-8993 (2022). The Clinical Use of Alzheimer's Disease Biomarkers in Patients with Mild Cognitive Impairment: A European Alzheimer's Disease Consortium Survey. J. Alzheimers Dis., 89 (2). S. 535 - 552. AMSTERDAM: IOS PRESS. ISSN 1875-8908

Full text not available from this repository.

Abstract

Background: Recent advances occurred in the field of Alzheimer's disease (AD) biomarkers and the introduction of a research framework grounded on a biomarker-based definition of AD might have fostered an increased clinical use of AD biomarkers. For this reason, an up-to-date depiction of the clinical use of AD biomarkers is needed. Objective: To investigate the clinical use of the main AD biomarkers in patients with mild cognitive impairment (MCI) by examining the beliefs and preferences of professionals (clinicians and biomarker experts) of the European Alzheimer's Disease Consortium (EADC). Methods: 150 professionals filled in an online survey from May to September 2020. The investigated biomarkers were medial temporal lobe atrophy score (MTA) on structural MRI, typical AD (i.e., temporoparietal and posterior cingulate) hypometabolism on FDG-PET, CSF (A(3 42 , p-tau, t-tau), amyloid-PET and tau-PET. Results: The frequency of responders reporting a frequent-to-constant use of MTA (77%) is higher than that of those reporting a frequent-to-constant use of the other AD biomarkers (i.e., CSF: 45%, p = 0.014; FDG-PET: 32%, p < 0.001; amyloid-PET: 8%, p < 0.001; and tau-PET: 2%, p < 0.001). CSF is considered the most valuable biomarker in terms of additional diagnostic value, followed by amyloid-PET, tau-PET, and typical AD hypometabolism on FDG-PET. Conclusion: AD biomarkers are widely used across European memory clinics with a clinical research background for the diagnosis of MCI. Overall, we observed that CSF is currently considered as the most useful biomarker, followed by amyloid-PET.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Caprioglio, Camilla UNSPECIFIED UNSPECIFIED UNSPECIFIED Garibotto, Valentina UNSPECIFIED UNSPECIFIED UNSPECIFIED Jessen, Frank UNSPECIFIED UNSPECIFIED UNSPECIFIED Froelich, Lutz UNSPECIFIED UNSPECIFIED UNSPECIFIED Allali, Gilles UNSPECIFIED UNSPECIFIED UNSPECIFIED Assal, Frederic UNSPECIFIED UNSPECIFIED UNSPECIFIED Frisoni, Giovanni B. UNSPECIFIED orcid.org/0000-0002-6419-1753 UNSPECIFIED Altomare, Daniele UNSPECIFIED orcid.org/0000-0003-1905-8993 UNSPECIFIED
URN:	urn:nbn:de:hbz:38-688383
DOI:	10.3233/JAD-220333
Journal or Publication Title:	J. Alzheimers Dis.
Volume:	89
Number:	2
Page Range:	S. 535 - 552
Date:	2022
Publisher:	IOS PRESS
Place of Publication:	AMSTERDAM
ISSN:	1875-8908
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language DIAGNOSIS; RECOMMENDATIONS; DEFINITION; GUIDELINES; UTILITY Multiple languages Neurosciences Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/68838